The Deal Register
Database › M&A › Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol…

M&A

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Lane
M&A
Announced
15 Jul 2026
Province
Ontario
Industry
Healthcare & life sciences
Status
Announced
What the filing says
Septa Pharmaceuticals Inc. , a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU ® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026.
Source

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe